73 research outputs found

    Introductory Chapter: Clostridium difficile Infection Overview

    Get PDF

    In vitro antagonistic activity of Lactobacillus casei against Helicobacter pylori

    Get PDF
    Abstract Helicobacter pylori is one of the most common causes of chronic infections in humans. Curing H. pylori infection is difficult because of the habitat of the organism below the mucus adherent layer of gastric mucosa. Lactobacilli are known as acid-resistant bacteria and can remain in stomach for a long time than any other organism, we aimed in this study to examine the efficacy of Lactobacillus casei as a probiotic against H. pylori in humans. Particularly, L. casei was opted as it is considered to be one of the widely used probiotics in dairy products. One hundred and seven strains of H. pylori were isolated from dyspeptic patients and were tested for their antibiotic susceptibility to metronidazole (MTZ), clarithromycin (CLR), tetracycline (TET), and amoxicillin (AMX) by the disc diffusion method. The strains were examined for their susceptibility toward L. casei -present in fermented milk products -by well diffusion method. It was found that 74.7% strains were resistant to MTZ; 1.8% to MTZ, TET, and CLR; 3.7% to MTZ and CLR; 4.6% to MTZ and TET; and 0.9% were resistant to MTZ, TET, and AMX. The antibacterial activity of L. casei against H. pylori was determined on all the tested H. pylori isolates including antibiotic resistant strains with different patterns. Our study proposed the use of probiotics for the treatment of H. pylori infection as an effective approach

    Effects of Electronic (e)-Cigarette Vapor on Staphylococcal Virulence: Are E-Cigarettes Safer than Conventional Cigarettes?

    Get PDF
    In recent years, electronic (e)ā€cigarettes have dramatically increased in popularity as an alternative to conventional cigarettes. Little is known about the effects of eā€cigarette vapor (EV) on bacteria that colonize the nasopharynx, including methicillinā€resistant Staphylococcusaureus (MRSA). As most cases of pneumonia can be traced to bacteria in a patient\u27s nasopharynx, increased virulence in potential pathogens could have direct consequences clinically for these patients. And because bacterial colonizers are spread between humans, increased virulence in one subject has implications for the community. There is accumulating evidence that exposure to cigarette smoke (CS) increases the pathogenicity of MRSA, as well as its dampening effects on the host immune system. EV exposure has also been demonstrated to increase MRSA virulence both invitro and in a murine model of pneumonia. In this chapter, we will compare the virulence changes reported in MRSA exposed to CS vs. those exposed to EV, as well as proposed mechanisms and therapeutic targets

    Coronavirus disease 2019 diagnostics: key to Africa's recovery

    Get PDF
    Ā© Copyright 2021, Mary Ann Liebert, Inc., publishersWith the coronavirus disease of 2019 (COVID-19) becoming a full-blown outbreak in Africa, coupled with many other challenges faced on the African continent, it is apparent that Africa continues to need diagnostics to enable case identification and recovery to this and future challenges. With the slow vaccination rates across the continent, reliable diagnostic tests will be in demand, likely for years to come. Thus, access to reliable diagnostic tools to detect the severe acute respiratory syndrome of the coronavirus-2 (SARS-CoV-2), the virus responsible for COVID-19, remain a critical pillar to monitor and contain new waves of COVID-19. Increasing the local capacity to manufacture and roll-out vaccines and decentralized COVID-19 testing are paramount for fighting the pandemic in Africa.SS is supported by an award from the Massachusetts Life Sciences Center Accelerating Coronavirus Testing Solutions (A.C.T.S). JG is funded by the African Academy of Sciences (Grants numbers GCA/MNCH/Round8/207/008 and SARSCov2-4-20-010) and the Royal Society, UK, Grant number FLR\R1\201314.info:eu-repo/semantics/publishedVersio

    Antigen-specific cytokine profiles for pulmonary Mycobacterium avium complex disease stage diagnosis

    Get PDF
    IntroductionControlling pulmonary Mycobacterium avium complex (MAC) disease is difficult because there is no way to know the clinical stage accurately. There have been few attempts to use cell-mediated immunity for diagnosing the stage. The objective of this study was to characterize cytokine profiles of CD4+T and CD19+B cells that recognize various Mycobacterium avium-associated antigens in different clinical stages of MAC.MethodsA total of 47 MAC patients at different stages based on clinical information (14 before-treatment, 16 on-treatment, and 17 after-treatment) and 17 healthy controls were recruited. Peripheral blood mononuclear cells were cultured with specific antigens (MAV0968, 1160, 1276, and 4925), and the cytokine profiles (IFN-Ī³, TNF-Ī±, IL-2, IL-10, IL-13, and IL-17) of CD4+/CD3+ and CD19+ cells were analyzed by flow cytometry.ResultsThe response of Th1 cytokines such as IFN-Ī³ and TNF-Ī± against various antigens was significantly higher in both the on-treatment and after-treatment groups than in the before-treatment group and control (P < 0.01ā€“0.0001 and P < 0.05ā€“0.0001). An analysis of polyfunctional T cells suggested that the presence of IL-2 is closely related to the stage after the start of treatment (P = 0.0309-P < 0.0001) and is involved in memory function. Non-Th1 cytokines, such as IL-10 and IL-17, showed significantly higher responses in the before-treatment group (P < 0.0001 and P < 0.01ā€“0.0001). These responses were not observed with purified protein derivative (PPD). CD19+B cells showed a response similar to that of CD4+T cells.ConclusionThere is a characteristic cytokine profile at each clinical stage of MAC

    COVID-19 vaccinology landscapeĀ inĀ Africa

    Get PDF
    More than two years after the start of COVID-19 pandemic, Africa still lags behind in terms vaccine distribution. This highlights the predicament of Africa in terms of vaccine development, deployment, and sustainability, not only for COVID-19, but for other major infectious diseases that plague the continent. This opinion discusses the challenges Africa faces in its race to vaccinate its people, and offers recommendations on the way forward. Specifically, to get out of the ongoing vaccine shortage trap, Africa needs to diversify investment not only to COVID-19 but also other diseases that burden the population. The continent needs to increase its capacity to acquire vaccines more equitably, improve access to technologies to enable local manufacture of vaccines, increase awareness on vaccines both in rural and urban areas to significantly reduce disease incidence of COVID-19 and as well as other prevalent diseases on the African continent such as HIV and TB. Such efforts will go a long way to reduce the disease burden in Africa

    Open Science ā€“ for whom?

    Get PDF
    Who can participate in Open Science and whose interests are served? Open Science in principle holds the potential to reduce inequality, but this is not going to happen unless it operates within a consistent framework and environment that supports this goal. Unequal power and opportunities from institutional to global level constitutes a major obstacle to human development, while we need to appreciate diversity as a key asset. How can we build an equitable global research ecosystem in accordance with the United Nations 2030 Agenda for Sustainable Development that recognises science as a global common good and an integral part of the shared cultural heritage of humankind?Publisher PDFPeer reviewe

    COVID-19 vaccinology landscape in Africa

    Get PDF
    More than two years after the start of COVID-19 pandemic, Africa still lags behind in terms vaccine distribution. This highlights the predicament of Africa in terms of vaccine development, deployment, and sustainability, not only for COVID-19, but for other major infectious diseases that plague the continent. This opinion discusses the challenges Africa faces in its race to vaccinate its people, and offers recommendations on the way forward. Specifically, to get out of the ongoing vaccine shortage trap, Africa needs to diversify investment not only to COVID-19 but also other diseases that burden the population. The continent needs to increase its capacity to acquire vaccines more equitably, improve access to technologies to enable local manufacture of vaccines, increase awareness on vaccines both in rural and urban areas to significantly reduce disease incidence of COVID-19 and as well as other prevalent diseases on the African continent such as HIV and TB. Such efforts will go a long way to reduce the disease burden in Africa.The Massachusetts Life Sciences Center Accelerating Coronavirus Testing Solutions, Nina Ireland Program for Lung Health, the Chan Zuckerberg Biohub Initiative and Africa Academy of Sciences funding for COVID-19 Research & Development goals for Africa.https://www.frontiersin.org/journals/immunologyam2023BiochemistryForestry and Agricultural Biotechnology Institute (FABI)GeneticsMicrobiology and Plant Patholog
    • ā€¦
    corecore